Clinical trial · Interventional
Adapted Physical Activity for Breast Cancer HER2 Positive Patient
Feasibility Study of an Adapted Physical Activity (APA) for Breast Cancer Patients Treated by Neoadjuvant Chemotherapy and Targeted Therapy Against HER2
NCT02963363CI-TRIAL-00071658APACAN2terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient recruitment
Summary
Brief summary (as posted)
The purpose of this study is to assess the feasibility of a home-based adapted physical activity during neoadjuvant chemotherapy for HER2+ breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2 Positive Breast Cancer | HER2-Positive Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Home-based Adapted Physical Activity | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Interventional
- description
- Home-Based Adapted Physical Activity intervention during neoadjuvant chemotherapy : 150 minutes per week of aerobic and muscle strengthening exercises during 18 weeks
- interventionNames
- Other: Home-based Adapted Physical Activity
Primary outcomes (1)
- measure
- Rate of patients reaching international physical activity recommendations for post-neoadjuvant chemotherapy assessment
- timeFrame
- Change from baseline (T0: before neoadjuvant chemotherapy) at the 5 months (T1: end of neoadjuvant chemotherapy)
- description
- Time spent to physical activity and sedentariness will be evaluated by Recent Physical Activity Questionnaire (RPAQ)
Secondary outcomes (12)
- measure
- Longitudinal evolution of RPAQ score
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women \> 18 years old * Patient with HER2 (Human Epidermal growth factor Receptor 2) positive breast cancer histologically proven, eligible for neoadjuvant chemotherapy and targeted therapy against HER-2 * Affiliation to the French social security scheme * Patient who signed the participation consent before entering the trial * Medical fitness certificate for sport Exclusion Criteria: * Diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer * Metastatic cancer * Karnofsky index ≤ 90% * Men * Pregnant women * Significant psychiatric or neurological abnormality * Patient deprived of liberty by a court or administrative * Contraindication for physical activity * Patient unable to complete questionnaires (language barrier) * Participation in a clinical trial with the same objective
References
Publications (1)
- DERIVEDGinzac A, Bernadach M, Molnar I, Duclos M, Thivat E, Durando X. Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study. Front Oncol. 2021 Dec 13;11:744609. doi: 10.3389/fonc.2021.744609. eCollection 2021. PMID 34966667